Changes in HDL cholesterol and cardiovascular outcomes after lipid modification therapy

Heart

Volumn 98, Issue 10, 2012, Pages 780-785

  Ray, Kausik ^a   Wainwright, Nick W J ^b,c   Visser, Loes ^d   Witteman, Jacqueline ^d   Breteler, Monique ^d   Ambegaonkar, Baishali ^e   Hofman, Albert ^d   Stricker, Bruno ^d   Wareham, Nick ^f   Khaw, Kay Tee ^g   Sandhu, Manjinder ^b,c  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e MERCK RESEARCH LABORATORIES   (United States)

^f ADDENBROOKE S HOSPITAL   (United Kingdom)

^g UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR PROCEDURE; CARDIOVASCULAR RISK; CIGARETTE SMOKING; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; HEART INFARCTION; HUMAN; LIPID MODIFICATION THERAPY; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RISK REDUCTION; STROKE; SYSTOLIC BLOOD PRESSURE; UNITED KINGDOM;

ADULT; AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; DYSLIPIDEMIAS; FEMALE; FOLLOW-UP STUDIES; GREAT BRITAIN; HUMANS; HYPOLIPIDEMIC AGENTS; MALE; MIDDLE AGED; MORBIDITY; NETHERLANDS; PORT-WINE STAIN; REGISTRIES; RISK FACTORS; SURVIVAL RATE;

EID: 84860916377     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2011-301405     Document Type: Article

References (25)

1. Di Angelantonio E, Sarwar N, Perry P, et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009;302:1993-2000.
2. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78.
3. Buchwald H, Varco RL, Matts JP, et al. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH). N Engl J Med 1990;323:946-55. (Pubitemid 20332334)
4. Rubins HB, Robins SJ, Collins D, et al The Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999;341:410-18. (Pubitemid 29362514)
5. Otvos JD, Collins D, Freedman DS, et al. Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation 2006;113:1556-63. (Pubitemid 43739414)
6. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987;317:1237-45. (Pubitemid 17147964)
7. Manninen V, Elo MO, Frick MH, et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA 1988;260:641-51.
8. Levy RI. Report on the Lipid Research Clinic trials. Eur Heart J 1987;8 (Suppl E):45-53. (Pubitemid 17141171)
9. Carlson LA, Rosenhamer G. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand 1988;223:405-18.
10. Robinson JG, Smith B, Maheshwari N, et al. Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis. J Am Coll Cardiol 2005;46:1855-62. (Pubitemid 41579807)
11. De Caterina R, Scarano M, Marfisi R, et al. Cholesterol-lowering interventions and stroke: insights from a meta-analysis of randomized controlled trials. J Am Coll Cardiol 2010;55:198-211.
12. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007;357:2109-22. (Pubitemid 350146106)
13. Grover SA, Kaouache M, Joseph L, et al. Evaluating the incremental benefits of raising high-density lipoprotein cholesterol levels during lipid therapy after adjustment for the reductions in other blood lipid levels. Arch Intern Med 2009;169:1775-80.
14. Day N, Oakes S, Luben R, et al. EPIC-Norfolk: study design and characteristics of the cohort. European Prospective Investigation of Cancer. Br J Cancer 1999;80 Suppl 1:95-103. (Pubitemid 29389613)
15. Hofman A, Grobbee DE, de Jong PT, et al. Determinants of disease and disability in the elderly: the Rotterdam Elderly Study. Eur J Epidemiol 1991;7:403-22.
16. Hofman A, Breteler M, Van Duijn C, et al. The Rotterdam Study: 2010 objectives and design update. Eur J Epidemiol 2009;24:553-72.
17. Seo SM, Choo EH, Koh YS, et al. High-density lipoprotein cholesterol as a predictor of clinical outcomes in patients achieving low-density lipoprotein cholesterol targets with statins after percutaneous coronary intervention. Heart 2011;97:1943-50.
18. Canner P, Berge K, Wenger N, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986;8:1245-55. (Pubitemid 17208898)
19. Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005;366:1849-61.
20. Ginsberg HN, Elam MB, Lovato LC, et al ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010;362:1563-74.
21. Jun M, Foote C, Lv J, et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet 2010;375:1875-84.
22. Burillo E, Andres EM, Mateo-Gallego R, et al. High-density lipoprotein cholesterol increase and non-cardiovascular mortality: a meta-analysis. Heart 2010;96:1345-51.
23. Sarwar N, Sandhu MS, Ricketts SL, et al. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet 2010;375:1634-9.
24. Whitlock G, Lewington S, Sherliker P, et al. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet 2009;373:1083-96.
25. Khera AV, Cuchel M, de la Llera-Moya M, et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med 2011;364:127-35.